Vir Biotechnology
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2016-04-07
- Employees
- 587
- Market Cap
- -
- Website
- http://www.vir.bio
- Introduction
Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.
Vir Biotechnology EVP vanina de Verneuil sells $624 in stock
Vanina de Verneuil sold 76 Vir Biotechnology shares at $8.2201 each, holding 56,973 shares post-transaction. The company, with a $1.15B market cap, is undervalued and has strong financials. Vir's hepatitis treatments received orphan drug designation, and R&D expenses rose to $195M due to a Sanofi licensing agreement. The company plans to initiate a hepatitis delta virus registrational program in 2025.
Vir has positive readthrough from Janux data, says Morgan Stanley
Morgan Stanley sees Janux Therapeutics' Phase 1a data as positive for Vir Biotechnology's TCE pipeline, with VIR-5818 and VIR-5500 data expected in Q1 2025. Vir shares up 24% pre-market.
Janux Therapeutics Stock Soars 70% on Prostate Cancer Drug Trial Results
Janux Therapeutics' stock surged 63% to $65.59 after reporting positive Phase I trial results for JANX007, a prostate cancer treatment. All 16 heavily pre-treated patients showed a 50% reduction in prostate-specific antigen levels. Analysts at William Blair rate Janux shares as Outperform, projecting peak sales of $3.0 billion for JANX007.
Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), PTC Therapeutics
Analysts maintain neutral ratings on Cytokinetics (CYTK), PTC Therapeutics (PTCT), and Vir Biotechnology (VIR), with price targets of $62.00, $45.00, and $10.00 respectively.
HepB-CpG vs HepB-Alum Vaccine in People With HIV and Prior Vaccine Nonresponse
HepB-CpG vaccine (2 or 3 doses) achieved superior HBV seroprotection in HIV-positive individuals with prior nonresponse to hepatitis B vaccine, compared to conventional HepB-alum vaccine (3 doses).
Related Clinical Trials:
Vir Biotechnology (NASDAQ:VIR) three-year losses have grown faster than shareholder ...
Vir Biotechnology's share price rose 12% in a week but is down 82% over three years. The company, unprofitable in the last twelve months, saw revenue drop 69% annually over the past three years, impacting the share price. Despite market gains, Vir Biotechnology's shareholders lost 18% in the last year and 6% annually over five years. Investors are advised to consider the business's fundamental metrics before investing.
Will Vir Biotechnology (NASDAQ:VIR) Spend Its Cash Wisely?
Vir Biotechnology had a cash runway of 23 months from September 2024 with $914m cash and $473m cash burn. Despite a 29% reduction in cash burn and concerns over revenue dip, the company's future growth prospects are promising, though shareholders should monitor cash burn closely.
Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN™ Masked T-Cell Engager Programs
Vir Biotechnology to host virtual investor event on Jan 8, 2025, discussing initial data from Phase 1 T-cell engagers VIR-5818 and VIR-5500, and updates on the PRO-XTEN™ platform.
© Copyright 2024. All Rights Reserved by MedPath